Vanguard Personalized Indexing Management LLC Grows Position in Gilead Sciences, Inc. $GILD

Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the 3rd quarter, Holdings Channel reports. The firm owned 199,160 shares of the biopharmaceutical company’s stock after acquiring an additional 5,132 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Gilead Sciences were worth $22,116,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of GILD. Norges Bank purchased a new position in Gilead Sciences in the second quarter worth $2,150,268,000. Ameriprise Financial Inc. lifted its stake in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after purchasing an additional 5,392,191 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after purchasing an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after purchasing an additional 2,169,266 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 3.7%

NASDAQ:GILD opened at $135.93 on Monday. The firm has a market capitalization of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a fifty day moving average of $123.98 and a 200 day moving average of $118.71. Gilead Sciences, Inc. has a 52 week low of $92.26 and a 52 week high of $136.30.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer directly owned 153,503 shares in the company, valued at approximately $18,727,366. This represents a 1.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. This represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 141,757 shares of company stock valued at $17,569,112 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Citigroup boosted their target price on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Scotiabank initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective for the company. Argus increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. Finally, Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $133.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.